ADVANCING A GROUND-BREAKING APPROACH TO AGONIST ANTIBODY THERAPEUTICS

Alex is the CEO of Diagonal and an Entrepreneur-in-Residence at Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts and an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

Patrick is a vascular biologist and the CSO of Diagonal. Patrick joins us from Pfizer where he most recently served as Vice President, CardioRenal Discovery. Prior to Pfizer, he served as Vice President, Biology at Acceleron Pharma through its acquisition by Merck. At Pfizer and Acceleron, Patrick led discovery programs and was instrumental in providing mechanistic proof of concept and translational assessments for the cardiac and pulmonary franchises, respectively. Before his tenure at Acceleron, Patrick was the Vice President, Biology and Pharmacology at Pliant Therapeutics, focusing on the development of therapeutics for TGFβ -mediated fibrotic diseases. Earlier in his career, Patrick spent over 15 years leading cardiometabolic disease programs at Merck and Portola pharmaceuticals. Patrick earned his Ph.D. in molecular and cellular biology of the blood vessel wall in Paris, France, performed his research fellowship at Harvard Medicine School.

Sandra is the Chief Development Officer of Diagonal Therapeutics. During her 20+ year career in biotech and pharma, she has had roles of increasing responsibility across development, development ops, strategy, portfolio & program management, and in vivo pharmacology at Wugen, Editas, Novartis, and Roche Vitamins. She has had extensive experience across therapeutics areas, including rare diseases, oncology, obesity, diabetes, and ophthalmology, as well as modalities from cell therapies, gene editing, biologics, to small molecules. She has an Advanced Certificate for Executives (ACE) in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D and MS from the University of Illinois, Urbana-Champaign, and a BS from the University of Porto, Portugal.

Eric is the SVP of Finance and Corporate Development at Diagonal, joining from Goldfinch Bio where he led the business development and commercial strategy functions and facilitated the out-license of Goldfinch’s lead assets to Karuna Therapeutics. Prior to Goldfinch, Eric held positions of increasing responsibility in new product planning and brand management, business development, and finance at Ironwood Pharmaceuticals, Cyclerion Therapeutics, and Ernst & Young. He received his undergraduate degree in biochemistry from the University of New Hampshire and an MBA in finance and marketing at the University of Massachusetts Amherst.

Melissa is the VP of drug discovery at Diagonal Therapeutics joining us from Biogen. She has over 15 years of experience designing and characterizing novel antibody therapeutics from early discovery to investigational new drug submissions. Melissa has also worked at Kiniksa Pharmaceuticals and Merrimack Pharmaceuticals in their early discovery groups. She was a postdoctoral fellow at the Whitehead Institute and received her Ph.D. in Biochemistry from Emory University.

JC is the Senior Director of Informatics at Diagonal. JC joined Diagonal from Biogen where he applied computational and structural biology to multiple modalities (biologics, small molecule, RNA, ASO). JC worked at the New York Structural Biology Center prior to Biogen. He received an Engineering Degree in Nuclear Physics from Grenoble INP - Phelma and a PhD in Biophysics from Université Joseph Fourier in France and completed his postdoc at Harvard University.